The Oxford-Harrington Rare Disease Centre has received a share of a £9.24 million investment for their research into chronic lymphocytic leukaemia (CLL).
The University’s Oxford Vaccine Group (OVG) is leading the development and trialling of a vaccine in response to the recent Ebola outbreak in the Democratic Republic of Congo (DR Congo).
Researchers led by University of Oxford academic Dr Wei Huang have successfully created biologically engineered cells, designed to target antimicrobial-resistant (AMR) bacteria.